Gainers Mobile-health Network (NASDAQ:MNDR) stock rose 370.0% to $4.0 during Monday's regular s

CervoMed Inc. (NASDAQ:CRVO) reported early results from its Phase 2a clinical study evaluating nefla

CervoMed reports a promising reduction in neuronal damage biomarkers during the first 12 weeks of it

Gainers Mobile-health Network (NASDAQ:MNDR) shares increased by 141.2% to $2.05 during Monday's

CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company) announced initial data showing a reduction in

CervoMed (NASDAQ: CRVO - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy a

CervoMed Inc. (NASDAQ: CRVO - Get Free Report) has earned a consensus recommendation of "Moderate Bu

New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposu

BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company fo

12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (I

12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (I

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnol

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy a

Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and lowers

CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.64) per share which missed the analyst conse

Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementi

BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnolo

Innovation Passport award designed to support accelerated time to market and help expedite patient a

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy a

New analyses of Phase 2b clinical trial reinforce treatment effect of neflamapimod observed relative

BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imag

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy a

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy a

CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-re

Interim biomarker data accepted for presentation at the 19 th Clinical Trials on Alzheimer's Disease

Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia

BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnolo

Gainers Tenon Medical (NASDAQ:TNON) shares increased by 115.8% to $0.76 during Monday's pre-mar

On June 18, 2026, CervoMed Inc., a Delaware corporation (the "Company"), entered into a Secu

CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-re

BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnolo

 CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-r

BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnolo

Explanation of Responses:1. On June 11, 2026, the Issuer completed a private placement (the "Pri

HITI rose sharply in pre-market trading on strong Q2 results and continued to rise after market open

BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnolo

Strategic priority is to establish a partnership to advance neflamapimod into Phase 3 in dementia wi

Additional funding will extend anticipated runway into second quarter of 2027 Strategic priority is

Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with

Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodeg